Ray Lin

1.7k citations

27 papers · 613 indexed · h-index 11

Impact in

Transplantation top 10%
Oncology top 10%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies

Papers in ⓘ

Oncology 11
- Cancer Immunotherapy and Biomarkers 4
- Lung Cancer Research Studies 2
Statistics and Probability 8
- Statistical Methods in Clinical Trials 7
- Statistical Methods and Inference 5
- Advanced Causal Inference Techniques 5

Co-authors: Larry Léon (5 shared papers)Susan D. Horn (1 shared paper)Rosemary A. Schaefer (1 shared paper)Eugen B. Hug (1 shared paper)Daniel W. Miller (1 shared paper)Sylvia K. Plevritis (1 shared paper)James M. Slater (1 shared paper)Jerry D. Slater (1 shared paper)
Journals: Statistics in Biopharmaceutical Research (3 papers)Cancer Research (2 papers)Journal of Clinical Oncology (2 papers)Cancer Discovery (1 paper)Scientific Reports (1 paper)
Partner nations: United States Switzerland Taiwan

In The Last Decade

Ray Lin

25 papers receiving 591 citations

Peers

Countries citing papers authored by Ray Lin

Since Specialization

Citations

This map shows the geographic impact of Ray Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ray Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ray Lin more than expected).

Fields of papers citing papers by Ray Lin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ray Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ray Lin. The network helps show where Ray Lin may publish in the future.

Co-authors

The 25 scholars most cited alongside Ray Lin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ray Lin Line = papers co-authored together Ray Lin links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 27 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC. Journal of Clinical Oncology ·Robert M. Jotte, Federico Cappuzzo, Ihor Vynnychenko, Daniil Stroyakovskiy, Delvys Rodríguez‐Abreu, Maen Hussein, Ross A. Soo, Henry Jacob Conter, Toshiyuki Kozuki, Carlos Alberto da Silva, Vilma Graupner, Shawn W. Sun, Ray Lin, Claudia Kelsch, Marcin Kowanetz, Tien Hoang, Alan N. Sandler, Mark A. Socinski	2018	170
2	Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors Cancer Discovery ·Dejan Juric, Ian E. Krop, Ramesh K. Ramanathan, Timothy R. Wilson, Joseph A. Ware, Sandra Sanabria Bohórquez, Heidi Savage, Deepak Sampath, Laurent Salphati, Ray Lin, Huan Jin, Hema Parmar, Jerry Y. Hsu, Daniel D. Von Hoff, José Baselga	2017	120
3	Conformal proton radiation therapy of the posterior fossa: a study comparing protons with three-dimensional planned photons in limiting dose to auditory structures International Journal of Radiation OncologyBiologyPhysics ·Ray Lin, Eugen B. Hug, Rosemary A. Schaefer, Daniel W. Miller, James M. Slater, Jerry D. Slater	2000	74
4	Single and multiple time-point prediction models in kidney transplant outcomes Journal of Biomedical Informatics ·Ray Lin, Susan D. Horn, John F. Hurdle, Alexander S. Goldfarb‐Rumyantzev	2008	48
5	Alternative Analysis Methods for Time to Event Endpoints Under Nonproportional Hazards: A Comparative Analysis Figshare ·Ray Lin, Ji Lin, Satrajit Roychoudhury, Keaven M. Anderson, Tianle Hu, Bo Huang, Larry Léon, Jason J. Z. Liao, Rong Liu, Xiaodong Luo, Pralay Mukhopadhyay, Rui Qin, Kay Tatsuoka, Xuejing Wang, Yan Wang, Jian Zhu, Tai‐Tsang Chen, Renee Iacona	2020	30
6	Estimation of treatment effects in weighted log-rank tests Contemporary Clinical Trials Communications ·Ray Lin, Larry Léon	2017	29
7	Comparing the benefits of screening for breast cancer and lung cancer using a novel natural history model Cancer Causes & Control ·Ray Lin, Sylvia K. Plevritis	2011	24
8	A phase Ib dose escalation study of combined inhibition of IDO1 (GDC-0919) and PD-L1 (atezolizumab) in patients (pts) with locally advanced or metastatic solid tumors. Journal of Clinical Oncology ·Howard A. Burris, Michael S. Gordon, Matthew D. Hellmann, Patricia LoRusso, Leisha A. Emens, F. Stephen Hodi, Christopher H. Lieu, Jeffrey R. Infante, Frank Tsai, Joseph P. Eder, James M. Cleary, Danijela Jelovac, Amy Lew Tsuhako, Lars Müeller, Ray Lin, Kari M. Morrissey, Sami Mahrus, Roland Morley, Andrea Pirzkall, S. Lindsey Davis	2017	24
9	346 Phase 1a study of the safety, pharmacokinetics, and pharmacodynamics of GDC-0919 in patients with recurrent/advanced solid tumors European Journal of Cancer ·Anupama Nayak, Zhonglin Hao, Ramses Sadek, Robin Dobbins, Lisa J. Marshall, Nicholas N. Vahanian, Jay Ramsey, Eugene P. Kennedy, Mario R. Mautino, Charles Link, Ray Lin, Stephanie Royer‐Joo, Kari M. Morrissey, Sami Mahrus, B. McCall, Andrea Pirzkall, David H. Munn, John E. Janik, Samir N. Khleif	2015	14
10	Using Web resources to construct multilingual medical thesaurus for cross-language medical information retrieval Decision Support Systems ·Wen‐Hsiang Lu, Ray Lin, Yi-Che Chan, Kuan-Hsi Chen	2007	10
11	Rejoinder to Letter to the Editor “The Hazards of Period Specific and Weighted Hazard Ratios” Statistics in Biopharmaceutical Research ·Ray Lin, Ji Lin, Satrajit Roychoudhury, Keaven M. Anderson, Tianle Hu, Bo Huang, Larry Léon, Jason J. Z. Liao, Rong Liu, Xiaodong Luo, Pralay Mukhopadhyay, Rui Qin, Kay Tatsuoka, Xuejing Wang, Yang Wang, Jian Zhu, Tai‐Tsang Chen, Renee Iacona, (unknown)	2020	10
12	Checkpoint Inhibition in the Treatment of Unresectable, Advanced Lymphoepithelioma-like Hepatocellular Carcinoma Journal of Clinical and Translational Hepatology ·David J. Hermel, Emma Du, Ray Lin, Catherine Frenette, Darren Sigal	2021	9
13	On Weighted Log-Rank Combination Tests and Companion Cox Model Estimators Statistics in Biosciences ·Larry Léon, Ray Lin, Keaven M. Anderson	2020	8
14	Methodologies for extracting functional pharmacogenomic experiments from international repository. PubMed ·Yi‐An Lin, Annie Chiang, Ray Lin, Peggy Yao, Rong Chen, Atul J. Butte	2007	7
15	Neoadjuvant chemotherapy and radiotherapy outcomes in borderline‐resectable and locally‐advanced pancreatic cancer patients Cancer Medicine ·Gregory P. Botta, Tridu R. Huynh, Samantha R. Spierling‐Bagsic, Alex Agelidis, Randolph Schaffer, Ray Lin, Darren Sigal	2022	6
16	Novel Noxipoint Therapy versus Conventional Physical Therapy for Chronic Neck and Shoulder Pain: Multicentre Randomised Controlled Trials Scientific Reports ·Charles C. Koo, Ray Lin, Tyng‐Guey Wang, Jau‐Yih Tsauo, Pan‐Chyr Yang, Chen‐Tung Yen, Sandip Biswal	2015	6
17	Overcoming terminology barrier using Web resources for cross-language medical information retrieval. PubMed ·Wen-Hsiang Lu, Ray Lin, Yi-Che Chan, Kuan-Hsi Chen	2006	6
18	A COMBINED DATA MINING APPROACH FOR INFREQUENT EVENTS: ANALYZING HIV MUTATION CHANGES BASED ON TREATMENT HISTORY PubMed ·Ray Lin, Soo‐Yon Rhee, Robert W. Shafer, Amar K. Das	2006	5
19	Abstract 1869: Novel TNFR2 antibodies to overcome T cell exhaustion and suppressive tumor microenvironment Cancer Research ·Chi Shing Sum, Makenzie Danton, Qii hu, Alla Pritsker, Ray Lin, Raymond Yu, Kevin Chen, Fangqiang Tang, Thomas Pohl, Samantha Wallner, Ahmed Hassan, Huarui Lu, Haichun Huang, James Pei, Zhong Liu, Han Li, Ming Lei	2021	4
20	Tri-modal management of primary small cell carcinoma of the pancreas (SCCP): a rare neuroendocrine carcinoma (NEC) BMC Gastroenterology ·Safa Elzein, Fei Bao, Ray Lin, Gabriel T. Schnickel, Andrew M. Lowy, Gregory P. Botta	2021	3

About Ray Lin

Ray Lin is a scholar working on Oncology, Statistics and Probability, Molecular Biology, Surgery and Pulmonary and Respiratory Medicine, having authored 27 papers that have together received 613 indexed citations. Recurring topics across this work include Statistical Methods in Clinical Trials (7 papers), Statistical Methods and Inference (5 papers), Advanced Causal Inference Techniques (5 papers), Cancer Immunotherapy and Biomarkers (4 papers), Biomedical Text Mining and Ontologies (3 papers), Natural Language Processing Techniques (2 papers), Lung Cancer Research Studies (2 papers) and Lung Cancer Treatments and Mutations (2 papers). The work is most often cited by research in Transplantation (30 citations), Oncology (280 citations), Biological Psychiatry (25 citations), Statistics and Probability (73 citations) and Pulmonary and Respiratory Medicine (272 citations). Ray Lin has collaborated with scholars based in United States, Switzerland and Taiwan. Frequent co-authors include Larry Léon, Susan D. Horn, Rosemary A. Schaefer, Eugen B. Hug, Daniel W. Miller, Sylvia K. Plevritis, James M. Slater, Jerry D. Slater, John F. Hurdle and Alexander S. Goldfarb‐Rumyantzev. Their work appears in journals such as Statistics in Biopharmaceutical Research, Cancer Research, Journal of Clinical Oncology, Cancer Discovery and Scientific Reports.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact